Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

LEUKOCARE Announces EUR 3.4 M Capital Increase

Published: Tuesday, September 03, 2013
Last Updated: Tuesday, September 03, 2013
Bookmark and Share
Fundraising ensures further execution of license-based business model.

LEUKOCARE has announced the successful completion of its capital increase of EUR 3.4 million. New ordinary shares were issued to existing shareholders and new investors in exchange for a combination of new equity capital and the conversion of an outstanding EUR 1.0 million corporate bond.

“This fundraising together with our increasing revenues allows us to accelerate the growth of our business and to drive the development of markets for our proven technology portfolio” explained Michael Scholl, CEO of LEUKOCARE.

Scholl continued, “It ensures the financial independence and operational flexibility of LEUKOCARE to reach the next milestones in the development of the company. In particular, in the next 2 years, we expect industrial partners in the fields of vaccines, combination products and biopharmaceuticals to start commercializing products employing our technologies. We are encouraged by the enthusiasm of our partners who have successfully evaluated LEUKOCARE’s technology platform and have initiated major product development efforts by licensing our proprietary technology and know-how.”

Based on LEUKOCARE’s Stabilizing and Protecting Solutions (SPS), biopharmaceutical products and vaccines can be significantly improved in respect to storage stability and quality.

Moreover, SPS allows terminal sterilization of biologics and of medical devices functionalized by biologically active substrates, including implant surfaces, wound dressings, and others.

LEUKOCARE’s recently submitted annual report stated a revenue growth of approx. 50 % representing the third consecutive year with an equivalent expansion rate.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Xenios and LEUKOCARE Announce Strategic Partnership
LEUKOCARE grants exclusive license on its innovative inflammation inhibition technology and develops a generic coating to be commercialized by Xenios in various extracorporeal therapy systems.
Thursday, October 03, 2013
Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!